Alzamend Neuro Inc Stock Price, News & Analysis

Alzamend Neuro has received FDA approval to proceed with a combined Phase 1 and 2 clinical trial for its Alzheimer’s treatment AL002. The therapy aims to utilize a mutant-peptide sensitized cell to enhance the immune system's ability to combat Alzheimer’s by reducing beta-amyloid plaques. Alzamend intends to file its IND application by the end of November 2021 and begin the clinical trial in early 2022, based on positive preclinical results and feedback from the FDA.

Alzamend Neuro has achieved a significant milestone by dosing the first group of participants in a six-month Phase I comparative study for AL001, aimed at treating dementia related to Alzheimer's disease. This study will assess the safety and pharmacokinetics of AL001 compared to conventional lithium treatments, involving at least 24 healthy participants. The company believes AL001 could offer significant improvements over existing therapies for the over 40 million Americans suffering from Alzheimer's.

Alzamend Neuro, Inc. (Nasdaq: ALZN) announced a partnership with Altasciences to conduct a six-month Phase I clinical study for AL001, aimed at treating dementia related to Alzheimer’s disease. The study, commencing in September 2021, will evaluate the pharmacokinetics of AL001 compared to a marketed lithium carbonate capsule. AL001 utilizes patented ionic cocrystal technology designed to enhance lithium delivery. Alzamend believes this formulation may significantly improve treatment options for Alzheimer’s and other neurodegenerative diseases, reducing potential regulatory burdens.

Alzamend Neuro, Inc. (Nasdaq: ALZN) announced an additional investment from Digital Power Lending, LLC, totaling $2 million for 1,333,333 shares at $1.50 each. This funding follows the FDA's approval for a Phase 1a study of AL001, a lithium-based therapy for Alzheimer's-related dementia. As part of a March 2021 agreement, further capital will be provided based on future milestones. CEO Stephan Jackman expressed gratitude for the support, indicating that the funding positions Alzamend well for advancing clinical trials without needing new capital.

Alzamend Neuro (Nasdaq: ALZN) has submitted a pre-IND meeting request to the FDA for AL002, a cell-based therapeutic vaccine aimed at combating Alzheimer’s by restoring the immune system's ability to fight the disease. Recent toxicology results have been positive, leading to plans for a Phase 1 clinical trial at Emory University School of Medicine to assess the treatment's safety and efficacy. This trial will enroll patients with early-stage Alzheimer’s for a year, including an interim statistical analysis after six months.

Alzamend Neuro (Nasdaq: ALZN) has received a favorable FDA study may proceed letter for its AL001 oral therapy aimed at treating dementia related to Alzheimer's disease. This Phase 1 trial is expected to commence in September 2021. AL001 utilizes a patented lithium-based ionic cocrystal technology, which has shown promising preclinical results, enhancing cognitive function and reducing behavioral issues in mice compared to traditional lithium treatments. The company’s pipeline also includes AL002, another innovative Alzheimer's treatment.

Alzamend Neuro, Inc. (Nasdaq: ALZN) announced positive results from a GLP toxicology study of its product AL002, aimed at treating Alzheimer’s disease. Conducted on a transgenic mouse model, the study showed no significant toxicity, with no treatment-related mortalities or adverse effects noted. CEO Stephan Jackman stated that these results are a critical milestone, as the company prepares to submit a Pre-Investigational New Drug Application for AL002 to the FDA. Alzamend aims to develop innovative treatments for neurodegenerative diseases at an affordable cost.

Alzamend Neuro (Nasdaq: ALZN) celebrates its recent Nasdaq listing by ringing the opening bell on July 12, 2021. The event is led by CEO Stephan Jackman and Chairman William B. Horne, marking a significant milestone for stockholders and the ongoing fight against Alzheimer’s disease. Alzamend has raised approximately $14.4 million through its IPO, which will fund operations and clinical trials. The company is advancing its therapeutic candidate, AL001, and aims to develop innovative treatments for Alzheimer's and other neurodegenerative diseases.

Ault Global Holdings announced that Alzamend Neuro submitted an IND application to the FDA for a Phase 1 clinical study of AL001, a lithium-based therapy for Alzheimer's-related dementia. This IND marks a significant step in Alzamend's pipeline development. Following this study, Alzamend plans a Phase 1/2a trial to assess safety and effectiveness. With over 47 million people affected by dementia globally, the economic burden is immense, costing the U.S. approximately $355 billion in 2021 alone. Ault holds 5.3 million shares of Alzamend, showing a strong commitment to the development of treatments for neurodegenerative diseases.